![]() We also discussed how his company’s C-Stem cell-encapsulation technology could promote iPSC expansion and differentiation in 3D culture formats, facilitating scale-up and improving stem-cell quality in turn.įeyeux was among the first doctoral students in France to work with PSCs and explore their applications in neurology. We focused especially on the needs of iPSCs during cell culture processes and the limitations associated with 2D culture systems, which remain the standard in the cell therapy industry. I spoke with Feyeux in January 2022 to explore considerations for increasing iPSC production. Thus, drug developers working with iPSCs today must choose between scaling out production using stacks of two-dimensional (2D) culture vessels or scaling up to three-dimensional (3D) bioreactors. Advanced-therapy products can require controlled proliferation and differentiation of millions or even billions of iPSCs depending on the clinical indication, he pointed out, yet culture methods and technologies for their stable mass production remain in early development stages ( 1, 2). But as I learned from Maxime Feyeux (cofounder and chief science officer of TreeFrog Therapeutics in Bordeaux, France), such cells are a relatively new option in the toolbox of cell therapy developers. Induced pluripotent stem cells (iPSCs) are promising starting materials for several clinical and industrial applications in cell therapy production, drug discovery, and in vitro screening. Photo 1: Production of 15 billion human induced pluripotent stem cells (iPSCs) in a 10-L bioreactor using the TreeFrog Therapeutics C-Stem technology, with 276-fold amplification in 6.59 days.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |